New insights into the burden and costs of multiple sclerosis in Europe: Results for Russia

Boyко, Alexey; Kobelt, Gisela; Berg, Jenny; Boyko, Olga; Popova, E. V.; Capsa, Daniela; Eriksson, Jennifer

doi:10.1177/1352458517708668

Cited by 26 publications

(35 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our initial search, conducted on 5 October 2019, retrieved 1099 records, of which only 11 articles [ 43 – 53 ] were deemed eligible. The COI study conducted in Russia was reported in two articles [ 13 , 47 ], and we excluded the article that presented the results of 16 mostly high-income European countries [ 13 ]. The search was rerun in July 2020, resulting in three additional eligible articles [ 54 – 56 ] for a total of 14 studies.…”

Section: Resultsmentioning

confidence: 99%

“…Table 1 summarizes the characteristics of included studies. They were conducted in ten countries: six in Latin America (Argentina [ 43 ], Colombia [ 50 ], Mexico [ 53 ], and three studies in Brazil [ 44 , 48 , 49 ]), seven in Asia (Turkey [ 45 ], Thailand [ 54 ], Jordan [ 51 ], two studies in Iran [ 46 , 55 ], and two studies in China [ 52 , 56 ]), and one in Russia [ 47 ]. All included studies were published between 2013 and July 2020 and reported on data collected between 2000 and 2018.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Economic Burden of Multiple Sclerosis in Low- and Middle‐Income Countries: A Systematic Review

Dahham

Rizk²,

Kremer

et al. 2021

PharmacoEconomics

View full text Add to dashboard Cite

Background Although the economic burden of multiple sclerosis (MS) in high-income countries (HICs) has been extensively studied, information on the costs of MS in low- and middle‐income countries (LMICs) remains scarce. Moreover, no review synthesizing and assessing the costs of MS in LMICs has yet been undertaken. Objective Our objective was to systematically identify and review the cost of illness (COI) of MS in LMICs to critically appraise the methodologies used, compare cost estimates across countries and by level of disease severity, and examine cost drivers. Methods We conducted a systematic literature search for original studies in English, French, and Dutch containing prevalence or incidence-based cost data of MS in LMICs. The search was conducted in MEDLINE (Ovid), PubMed, Embase (Ovid), Cochrane Library, National Health Service Economic Evaluation Database (NHS EED), Econlit, and CINAHL (EBSCO) on July 2020 without restrictions on publication date. Recommended and validated methods were used for data extraction and analysis to make the results of the COI studies comparable. Costs were adjusted to $US, year 2019 values, using the World Bank purchasing power parity and inflated using the consumer price index. Results A total of 14 studies were identified, all of which were conducted in upper-middle-income economies. Eight studies used a bottom-up approach for costing, and six used a top-down approach. Four studies used a societal perspective. The total annual cost per patient ranged between $US463 and 58,616. Costs varied across studies and countries, mainly because of differences regarding the inclusion of costs of disease-modifying therapies (DMTs), the range of cost items included, the methodological choices such as approaches used to estimate healthcare resource consumption, and the inclusion of informal care and productivity losses. Characteristics and methodologies of the included studies varied considerably, especially regarding the perspective adopted, cost data specification, and reporting of costs per severity levels. The total costs increased with greater disease severity. The cost ratios between different levels of MS severity within studies were relatively stable; costs were around 1–1.5 times higher for moderate versus mild MS and about two times higher for severe versus mild MS. MS drug costs were the main cost driver for less severe MS, whereas the proportion of direct non-medical costs and indirect costs increased with greater disease severity. Conclusion MS places a huge economic burden on healthcare systems and societies in LMICs. Methodological differences and substantial variations in terms of absolute costs were found between studies, which made comparison of studies challenging. However, the cost ratios across different levels of MS severity were similar, making comparisons between studies by disease severity feasible. Cost drivers were mainly DMTs and...

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Economic Burden of Multiple Sclerosis in Low- and Middle‐Income Countries: A Systematic Review

Dahham

Rizk²,

Kremer

et al. 2021

PharmacoEconomics

View full text Add to dashboard Cite

show abstract

“…For clarity and transparency, in Supplementary Table 1 and 2 we have added a detailed summary of resources use during the relapse phase and by EDSS category, as provided by KOLs. For validity check, we compared the derived estimates from KOL to recently published data on MS costs in Russia [ 49 ] where costs are expected to be more similar to those in China than another high-income Western country. The Russia study reports direct costs (excluding DMT) of approximately US$1670 for mild severity patients EDDS 0–3; US$3220 for moderate severity patients EDSS 4–6.5, and US$7800 for severe patients of EDSS 7–9 [ 49 ].…”

Section: Discussionmentioning

confidence: 99%

“…For validity check, we compared the derived estimates from KOL to recently published data on MS costs in Russia [ 49 ] where costs are expected to be more similar to those in China than another high-income Western country. The Russia study reports direct costs (excluding DMT) of approximately US$1670 for mild severity patients EDDS 0–3; US$3220 for moderate severity patients EDSS 4–6.5, and US$7800 for severe patients of EDSS 7–9 [ 49 ]. These costs are comparable to those derived from the Chinese KOL survey with US$884 average for the management of mild patients, US$5237 for moderate severity patients, and US$7648 for severe patients in our study.…”

Section: Discussionmentioning

confidence: 99%

Cost-effectiveness of Teriflunomide Compared to Interferon Beta-1b for Relapsing Multiple Sclerosis Patients in China

Ningying

Chirikov

et al. 2019

Clin Drug Investig

View full text Add to dashboard Cite

Background and Objective Teriflunomide is a once-daily oral immunomodulatory agent approved in 80 countries for the treatment of patients with relapsing multiple sclerosis (RMS). The study objective was to estimate the cost effectiveness of teriflunomide (14 mg tablet, daily) versus interferon beta-1b (250 mcg subcutaneous injection, every other day) among RMS patients from the Chinese healthcare system perspective. Methods A Markov model with annual cycles and a lifetime horizon was utilized to assess cost-effectiveness of teriflunomide in comparison with interferon beta-1b in RMS patients. Treatment effects, including 3-month confirmed disability worsening and annualized relapse rate, were derived from a network meta-analysis. Cost inputs included costs related to treatment acquisition, administration, monitoring, natural disease management through Expanded Disability Status Scale states, relapse treatment, and adverse event management. These costs were calculated as the product between unit costs from published sources and healthcare resource utilization patterns identified in a survey conducted among 11 neurologists across different areas in China. Health effects were expressed as quality-adjusted life years (QALYs) with costs in local currency (¥) and US dollars (US$), 2018. Results Teriflunomide dominated interferon beta-1b and was associated with lower total costs (teriflunomide ¥1,887,144 vs interferon beta-1b ¥2,061,393) and higher QALYs (teriflunomide 9.60 QALYs vs interferon beta-1b 8.88 QALYs). In probabilistic sensitivity analysis, teriflunomide was dominant in 62.2% of model runs. Conclusion Teriflunomide is a cost-effective therapy over a lifetime time horizon compared to interferon beta-1b in the treatment of RMS patients in China. Results should be interpreted with caution as head-to-head comparisons are not available. Electronic supplementary material The online version of this article (10.1007/s40261-019-00750-3) contains supplementary material, which is available to authorized users.

show abstract

“…в год, при тяжелой форме РС -более 1 млн руб. в год [4]. Высокая медико-социальная значимость проблемы РС обусловлена тем, что заболеванием страдают в большинстве молодые люди, которые могли бы вести активную трудовую и социальную деятельность [3,5].…”

Section: обзорыunclassified

Treatment of a spastic increase of muscle tone in multiple sclerosis with botulinum toxin

Костенко¹,

Бойко²

2018

Z. nevrol. psikhiatr. im. S.S. Korsakova

View full text Add to dashboard Cite

The article presents data of the reviews, consensus and recommendations on the use of botulinum toxin type A (BTA) in multiple sclerosis (MS) patients with spasticity syndrome. It presents the results of randomized clinical trials that confirm the efficacy and favorable safety profile of dysport in treatment of MS patients. The complex approach to spasticity therapy and rehabilitation in MS is discussed.

show abstract

New insights into the burden and costs of multiple sclerosis in Europe: Results for Russia

Abstract: This study illustrates the burden of MS on Russian patients and provides current data that are important for developing health policies.

Cited by 26 publications

References 11 publications

Economic Burden of Multiple Sclerosis in Low- and Middle‐Income Countries: A Systematic Review

Economic Burden of Multiple Sclerosis in Low- and Middle‐Income Countries: A Systematic Review

Cost-effectiveness of Teriflunomide Compared to Interferon Beta-1b for Relapsing Multiple Sclerosis Patients in China

Treatment of a spastic increase of muscle tone in multiple sclerosis with botulinum toxin

Contact Info

Product

Resources

About